Hours

Minutes

Seconds

-40%

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Market Cap	2.58B 381M 329M 304M 284M 532M 36.25B 541M 3.58B 1.4B 17.64B 1.43B 1.4B 61.09B	P/E Ratio 2024	-8.86x	P/E Ratio 2025	-9.48x
Enterprise Value	2.8B 413M 357M 329M 308M 577M 39.3B 586M 3.89B 1.51B 19.13B 1.55B 1.52B 66.23B	EV / Sales 2024	1.48x	EV / Sales 2025	1.79x
Free-Float	67.99%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Timeframe

Style

Dynamic Chart

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

04-22	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
29/10/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
18/09/25	Authorities Lift Suspension Order on Yibai Pharma's Production, Sales of Children's Cough Syrup	MT
20/08/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
06/08/25	Yibai Pharmaceutical Gets Order to Suspend Marketing of Children's Cough Syrup	MT
25/04/25	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
28/11/24	Guizhou Yibai Pharmaceutical Co., Ltd. 's Equity Buyback announced on November 29, 2023 has expired.	CI
25/10/24	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
10/10/24	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI
09/09/24	Guizhou Yibai Pharmaceutical CFO Steps Down; Successor Named	MT
04/09/24	Guizhou Yibai Pharmaceutical Gets China Approval for Multiple, Non-Hodgkin's Lymphoma Drug	MT
23/08/24	Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
03/07/24	Tranche Update on Guizhou Yibai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	CI

More news

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Ya Qi Dou CEO	Chief Executive Officer	42	13/05/2021
Xianti Zeng DFI	Director of Finance/CFO	52	06/09/2024
Zhi Wei Wang PRN	Corporate Officer/Principal	56	17/09/2019

Director	Title	Age	Since
Qi Ling Dou CHM	Chairman	66	22/01/2009
Zhi Wei Wang BRD	Director/Board Member	56	21/02/2011
Ya Qi Dou BRD	Director/Board Member	42	03/01/2019

More insiders

Guizhou Yibai Pharmaceutical Co Ltd is a China-based company principally engaged in pharmaceutical industry, medical services, and big health industry businesses. The pharmaceutical industry business is mainly engaged in the research and development, production and sales of chemical drugs, traditional Chinese medicines, biological drugs and other drugs. The medical service business is mainly engaged in the operation and management of comprehensive hospitals, tumor specialty hospitals, and tumor radiotherapy centers. The big health industry business is mainly engaged in the development, research, production and sales of big health products featuring Miao medicine. The Company mainly operates its businesses in the domestic market.

Employees

4,832

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	3.290 ¥	+1.23%	16,588,380
11/06/26	3.250 ¥	-1.81%	14,354,220
10/06/26	3.310 ¥	-0.60%	14,407,180
09/06/26	3.330 ¥	-0.60%	17,710,608
08/06/26	3.350 ¥	-2.90%	18,266,066

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shanghai S.E. Other stock markets 12/06/2026			5-day change	1st Jan Change
3.290 ^CNY	+1.23%		-4.64%	-17.34%

1 day	+1.23%
1 week	-4.64%
Current month	-7.06%
1 month	-20.72%
3 months	-17.54%
6 months	-16.07%
Current year	-17.34%

1 week	3.18	3.48
1 month	3.18	3.99
Current year	3.18	5.27
1 year	3.18	5.27
3 years	2.76	6.15
5 years	2.76	8.8
10 years	2.76	20.3

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD.	+1.23%	-4.64%	-16.50%	-36.73%	381M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+38.28%	+154.20%	1,010B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.32%	+49.85%	580B
ABBVIE INC.	+1.32%	+0.22%	+19.18%	+64.65%	402B
ROCHE HOLDING AG	+0.77%	0.00%	+21.28%	+16.70%	330B
NOVARTIS AG	+0.44%	+3.48%	+25.65%	+35.66%	281B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.54%	+14.67%	280B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.35%	-47.35%	197B
AMGEN INC.	+0.32%	+1.61%	+20.32%	+60.01%	192B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+14.19%	+60.09%	156B
Average	+0.33%	+0.58%	+15.39%	+37.17%	342.93B
Weighted average by Cap.	-0.23%	+1.03%	+27.76%	+70.53%

	2024	2025
Net sales	2.17B 321M 277M 256M 239M 449M 30.54B 455M 3.02B 1.18B 14.86B 1.21B 1.18B 51.46B	1.86B 275M 238M 219M 205M 384M 26.17B 390M 2.59B 1.01B 12.74B 1.03B 1.01B 44.1B
Net income	-317M -46.88M -40.49M -37.31M -34.92M -65.45M -4.46B -66.46M -441M -172M -2.17B -176M -172M -7.51B	-330M -48.7M -42.06M -38.76M -36.28M -68M -4.63B -69.05M -458M -178M -2.25B -183M -179M -7.8B
Net Debt	411M 60.72M 52.44M 48.33M 45.24M 84.77M 5.77B 86.09M 571M 222M 2.81B 228M 223M 9.73B	217M 32.08M 27.71M 25.54M 23.9M 44.79M 3.05B 45.49M 302M 118M 1.48B 120M 118M 5.14B

Guizhou Yibai Pharmaceutical Co., Ltd. Stock

Stocks

600594

CNE000001H03

Pharmaceuticals

Valuation: Guizhou Yibai Pharmaceutical Co., Ltd.

Chart: Guizhou Yibai Pharmaceutical Co., Ltd.

Latest news : Guizhou Yibai Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Guizhou Yibai Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates